-
ICT 2023 Speakers Presentations
Manhattan | Broadway |
| Extracellular vesicles in CAT pathogenesis Elena Campello | What have we learned from GWAS studies on hemostatic factors María Sabater |
| Assessment of bleeding risk Ricardo Pinto | Circulating miRNAs in the pathophysiology of atherosclerosis and thrombosis Teresa Padró |
| Tailoring anticoagulation beyond six months Carmen Font | DIC a thrombotic microangiopathy in sepsis and COVID-19 Vilma Grilo |
| Is there a place for P2Y12 pre-treatment in STEMI? Eduardo Oliveira | Future development on antithrombotic treatment: new options for improvement Gemma Vilahur |
| Antithrombotic treatment beyond the first year of ACS Andrea Rubboli | Soluble Biomarkers of thrombosis in covid-19 Antonella Tufano |
| Thrombotic and bleeding risk in CAR-T cell therapy Mertixell Nomdedéu | The interplay between inflammation and thrombosis in COVID-19 Melanie Ferreira |
| Guided anti platelet therapy in patients undergoing PCI Marco Cattaneo | Sepsis, thrombosis and organ dysfunction Vittorio Pengo |
| OR-27 Effect of EPA, DOACs and their combination on platelet activation Alexandros Tselepis |
Manhattan | Broadway |
| Anticoagulation in mesenteric thrombosis Luis Jara Palomares | The power of antiplatelet agents to target the infarcted heart: Potential role beyond thrombosis Gemma Vilahur |
| Indications for endovascular management in VT João Valença | Factor XI in arterial disease Bianca Rocca |
| Patients with cancer at risk of thrombocytopenia Sérgio Barroso | Thrombosis in Hemoglobinopathies Ana Freixo |
| Anticoagulant treatment of paediatric patients Maria João Palare | Cancer-associated pulmonary embolism Carme Font |
| How the molecular diagnosis can help you? Teresa Fidalgo | Antineoplastic treatment modalities: Effects on coagulation Ismail Elalamy |
| How long should we treat children with DVT? Anabela Ferrão | Antiphospholipid syndrome Vittorio Pengo |
| Aspirin in the primary prevention setting João Morais | Personalized medicine in thrombosis Bianca Rocca |
| Pregnancy and need for anticoagulation Farjah AlGahtani | |
| Reversal agents, new developments Luciana Gonçalves | |
| Anticoagulation and bleeding in ECMO Ana Rita Rodrigues | |
| The perspective of a basic-translational scientist Gemma Vilahur | |
| The perspective of a clinical-laboratory approach Teresa Fidalgo |
Manhattan | Broadway |
| Thrombosis in women: Gender differences Alexandros Tselepis | VTE and pregnancy Matija Kozak |
| NETS and thromboinflammation Teresa Padró | Catheter-directed therapies for the treatment of pulmonary embolism Rita Calé |
| Monotherapy after acute coronary syndromes. Less is more? Andrea Rubboli | Factor XI a new target for antithrombotic therapy Vittorio Pengo |
| Bleeding Risk Assessment in end-stage kidney disease Daniel Caldeira | Risk of thrombosis in pediatric patients with inflammatory bowel disease Jorge Amil |
| Left atrial appendage closure for stroke prevention Eduadro Oliveira | |
| From initial suspicion to long-term follow-up? José Pedro Carda | |
| Diagnosis and clinical practice. The role of registries and the sharing of experience María Eva Mingot | |
| Mechanical valve prosthesis and major bleeding Cristina Gavina | |
| Transcatheter valve replacement in the very old population Lluís Asmarats | |
| Invasive procedures in patients with high bleeding risk Fernando Sá |